Smaller, Better, Faster, Stronger: the "Antibodies" of the Future | Antibodies Mini-Series Part 3

Antibodies are crucial proteins used by the immune system to neutralize threats. Scientists have improved their effectiveness, but monoclonal antibodies have limitations like fragility and size. Researchers are exploring smaller, more stable alternatives, such as mini binders and plastic antibodies. Mini binders, designed using machine learning, offer advantages like higher stability and potential nasal administration. Plastic antibodies, though less specific, are cheap and stable. These innovations could revolutionize medical treatments and diagnostics, expanding the applications of antibody technologies.

What is a major drawback of monoclonal antibodies?

• They are fragile and sensitive to high temperatures.

• They are too small to be effective.

• They are not specific to any antigen.

• They are easy to administer orally.

What is a key advantage of antigen binding fragments (fabs)?

• They are more fragile than traditional antibodies.

• They can reach locations in the body that larger antibodies cannot.

• They are larger than traditional antibodies.

• They are less specific than traditional antibodies.

What is the primary goal of researchers developing mini binders?

• To create antibodies that are more fragile.

• To develop antibodies that are less specific.

• To design proteins that are smaller and more stable than traditional antibodies.

• To create antibodies that are larger and more complex.

What is a potential advantage of mini binders over traditional antibodies?

• They are more expensive to produce.

• They are more fragile and sensitive to temperature.

• They can be administered by nose spray instead of injection.

• They are less specific to antigens.

What is a unique feature of plastic antibodies?

• They are made from natural proteins.

• They are cheap to make and incredibly stable.

• They are less stable than traditional antibodies.

• They are smaller than traditional antibodies.

What is a limitation of the current process for making plastic antibodies?

• It requires a small amount of the target antigen.

• It is very inexpensive.

• It does not require any target antigen.

• It requires a large amount of the target antigen.

How have antibody technologies evolved since the 19th century?

• They have advanced significantly, treating various diseases and conditions.

• They have become less specific and less stable.

• They are no longer used in medicine.

• They have remained largely unchanged.